GSK reported positive data Friday from a B7-H3-targeting asset partnered with Hansoh Pharmaceutical Group Co. The Phase III ARTEMIS-008 trial run in China is testing the antibody-drug conjugate (ADC) risvutatug rezetecan (ris-rez) and has succeeded on its primary endpoint of overall survival (OS) in patients with advanced or relapsed small-cell lung cancer (SCLC), the UK drugmaker said. Hansoh will use the results to back its request for regulatory approval in China. GSK acquired ex-China righ

—Cooperative Research and Development Agreement (CRADA) will utilize Apertura's TfR1 CapX™ Capsid— —Ara Parseghian Medical Research Fund, a non-profit organization dedicated to finding a treatment or cure for Niemann-Pick Type C, will contribute financial support to the research— July 9, 2026 -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced that it has entered into a Cooperative Research and Development Ag

In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered symptom burden in patients with chronic obstructive pulmonary disorder. AstraZeneca has gone on another excursion to Asia, this time enlisting Sino Biopharmaceutical for a global licensing deal to address a chronic respiratory disorder. The pharma is paying $200 million upfront and offering up to $1.9

Vertex Pharmaceuticals is making the largest acquisition bet in its history, announcing late Monday an agreement to purchase a biotechnology company, Crinetics Pharmaceuticals, that recently brought to market a new kind of medicine for a rare hormonal disorder. Vertex is paying $85 per share in cash, or $10 billion overall, for Crinetics. The deal ranks as the fourth largest, by total proceeds, in an already busy year for biotech company acquisitions, according to BioPharma Dive data. Additiona

July 7, 2026 -- Helix, the leading enterprise genomics company, today announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company. Under this agreement AstraZeneca will gain access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas. GenoSphere cohorts consist of comprehensive Exome+® genomic and rich longitudinal clinical data, designed to accelerate Life Sciences research across the development cycle. The

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas July 1, 2026 -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas. The collaboration is designed to identify clinically differentiated drug candidates for pr

United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the immune system, including training T-cells, which are essential for

June 30, 2026 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced the closing of the plan of arrangement (announced on November 19, 2025 and February 24, 2026) pursuant to which HS North America Ltd. (the “Purchaser”), a wholly owned subsidiary of Hanmi Pharmaceutical Co. Lt

Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined company at closing anticipated to fund TALA-125 through a Phase 2b proof-of-concept study data readout in the second half of 2028 Talawar, the first company formed to develop and commercialize assets discovered by Khanda Therapeutics, L.P. ("Khanda"), is developing TALA-125, a novel anti-IL-13 × anti-IL-18 bispecific antibody for atopic dermatitis, with clinical entry expected

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk Transaction expected to be accretive to earnings and cash flow upon closing. YUPELR® U.S. profit share and ex-U.S. royalti